These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10155601)

  • 1. Cost effectiveness of hepatitis A prevention in France.
    Severo CA; Fagnani F; Lafuma A
    Pharmacoeconomics; 1995 Jul; 8(1):46-61. PubMed ID: 10155601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of hepatitis A vaccination in Dutch military personnel.
    Buma AH; Beutels P; van Damme P; Tormans G; van Doorslaer E; Leentvaar-Kuijpers A
    Mil Med; 1998 Aug; 163(8):564-7. PubMed ID: 9715622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic assessment of pre-vaccination screening for hepatitis A and B.
    Jacobs RJ; Saab S; Meyerhoff AS; Koff RS
    Public Health Rep; 2003; 118(6):550-8. PubMed ID: 14563912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.
    Das A
    Hepatology; 1999 Feb; 29(2):548-52. PubMed ID: 9918934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of hepatitis A prevention in travellers.
    Tormans G; Van Damme P; Van Doorslaer E
    Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.
    Chodick G; Lerman Y; Wood F; Aloni H; Peled T; Ashkenazi S
    J Occup Environ Med; 2002 Feb; 44(2):109-15. PubMed ID: 11851212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination.
    Saab S; Martin P; Yee HF
    Am J Med; 2000 Aug; 109(3):241-4. PubMed ID: 10974188
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidemiology and prevention of hepatitis A in travelers.
    Steffen R; Kane MA; Shapiro CN; Billo N; Schoellhorn KJ; van Damme P
    JAMA; 1994 Sep; 272(11):885-9. PubMed ID: 8078167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of screening serology in anti-hepatitis A vaccination of travelers].
    Landry P; Darioli R
    Schweiz Med Wochenschr; 1998 Apr; 128(15):581-5. PubMed ID: 9606799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination.
    Gutersohn T; Steffen R; Van Damme P; Holdener F; Beutels P
    Aviat Space Environ Med; 1996 Feb; 67(2):153-6. PubMed ID: 8834941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of vaccination against hepatitis A for frequent travellers.
    Fenn P; McGuire A; Gray A
    J Infect; 1998 Jan; 36(1):17-22. PubMed ID: 9515663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should British soldiers be vaccinated against hepatitis A? An economic analysis.
    Jefferson TO; Behrens RH; Demicheli V
    Vaccine; 1994 Nov; 12(15):1379-83. PubMed ID: 7887014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of hepatitis A vaccination in healthcare workers.
    Smith S; Weber S; Wiblin T; Nettleman M
    Infect Control Hosp Epidemiol; 1997 Oct; 18(10):688-91. PubMed ID: 9350460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults.
    O'Connor JB; Imperiale TF; Singer ME
    Hepatology; 1999 Oct; 30(4):1077-81. PubMed ID: 10498662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1996 Dec; 45(RR-15):1-30. PubMed ID: 9005304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.